If you or a loved one has suffered a serious Xeljanz side effect, you may be entitled to financial compensation. A lawyer from the Showard Law Firm can help you explore your legal options. The firm offers free case reviews. This initial consultation is confidential and does not cost you a thing.
A Xeljanz Lawsuit can be filed against the pharmaceutical company that manufactured the drug. The manufacturer of the drug has a duty to warn consumers about its risks and side effects. The warnings should include information about how to safely use the drug. An attorney can help determine if you have a strong case and the value of your claim.
Many individuals have filed Xeljanz lawsuits against Pfizer Pharmaceuticals, the company that produced and sold the drug. These lawsuits claim that Pfizer failed to adequately research and warn about potential risks of the drug, and failed to provide adequate warnings for patients and medical professionals. If Pfizer had provided the public with accurate information about the risks of the drug, doctors would have been able to make a more informed decision on whether to prescribe it to their patients.
Xeljanz lawsuits can be filed on behalf of people who have suffered serious side effects from the medication. Some of these side effects include pulmonary embolism, deep vein thrombosis, stroke, and blood clot-related injuries. The amount of money a person can receive for a Xeljanz lawsuit depends on the amount of damage they suffered.
A growing number of Xeljanz lawsuits are being filed by patients who were prescribed the drug but suffered adverse effects. Some of these lawsuits claim that the drug’s labeling was not adequate or that warnings were not provided about the potential risks. These lawsuits are filed in response to recent changes in Pfizer’s Xeljanz labeling, and the lawsuits may satisfy the requirements of a failure to warn claim.
To file a lawsuit, a Xeljanz user must prove that the drug caused a serious health problem. The plaintiff must have sustained financial loss as a result of the drug’s effects. In addition, the lawsuit must show that the Xeljanz user suffered pain and suffering.
Xeljanz lawsuits have been filed in all 50 states. While the FDA has approved the drug for severe and moderate ulcerative colitis, it has been linked to a variety of adverse effects. Some of these effects include:
Pfizer omitted sepsis data from clinical trials
The Xeljanz Lawsuit claims that Pfizer knew of the risk of sepsis, yet failed to warn patients of the risk. Even though the drug carries a boxed warning, plaintiffs argue that the drug maker knew more about the risk of sepsis than it is letting on. The company also failed to notify the FDA of the adverse reactions associated with Xeljanz. As a result, thousands of plaintiffs have filed claims. Until a jury decides on the merits of the claims, these lawsuits are largely settled individually.
The Plaintiffs alleged that Defendant should have been aware of a higher risk of sepsis after Xeljanz had been approved. The lawsuit also alleges that Pfizer failed to warn doctors about the risk of sepsis and other serious infections associated with the drug. However, Pfizer counters that the Plaintiffs’ allegations are not supported by any evidence.
The Court’s decision will be based on two aspects of the lawsuit: pre-approval and post-approval. In the former, the Defendant had the option to submit a stronger warning label for Xeljanz at the same time as it submitted its initial application to the FDA. However, the Defendant argues that the pre-approval preemption doctrine preempts state law claims and requires it to comply with FDA regulations.
Pfizer failed to notify FDA of adverse reactions to Xeljanz
There are a number of adverse effects associated with the drug Xeljanz. One of the most serious of these is sepsis, which is a potentially fatal condition. As a result, the FDA has issued a warning to consumers. The warning applies to patients taking Xeljanz at doses between 5 mg and 10 mg. A lawsuit filed by Marilyn Stube alleges that she took Xeljanz for four years before developing sepsis. Eventually, she underwent multiple organ failure and gangrene, and she lost her legs and feet.
Hundreds of lawsuits allege that Pfizer failed to properly inform the FDA about the risks associated with Xeljanz. This is because Pfizer knew that a higher dose of the drug could cause blood clots, but failed to disclose this fact. In addition, Pfizer failed to warn consumers that higher doses could cause serious cardiovascular side effects. If enough Xeljanz lawsuits are filed, the case could be tried in a class action lawsuit.
The adverse reactions associated with Xeljanz have forced Pfizer to pull the drug from the market. It is one of the Janus kinase inhibitors (JAK inhibitors), which suppresses the body’s immune system and prevents joint damage. The drug was approved by the FDA in 2012 and has since been used to treat psoriatic arthritis and ulcerative colitis.